Listed

Aclaris Therapeutics, Inc.

ACRSNasdaqCIK 1557746HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$1.6mRevenue, Q2 FY2026, three months to 2026-06-30$1.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 6, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$1.6mRevenue, Q2 FY2026, three months to 2026-06-30$1.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure−8.3% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin−1487.9%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$24.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Revenue: $1.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure−452.0 pts on a year earlier
  • Net margin−1320.1%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$21.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Revenue: $1.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure−451.9 pts on a year earlier
  • Diluted EPS−$0.15Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure−15.4% on a year earlier
  • Free cash flow−$19.9mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$19.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001104659-26-092065. Derived: 6-month figure less the 3-month figure.Capital expenditure: $58.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001104659-26-092065. Derived: 6-month figure less the 3-month figure.Report this figure−98.8% on a year earlier

Last eight quarters

Full statements
Revenue$1.6mOperating margin −1487.9%
Diluted EPS−$0.15, Q2 FY2026
Free cash flow−$19.9m, Q2 FY2026
Aclaris Therapeutics, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m4.3Revenue, Q3 FY2024, three months to 2024-09-30$4.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure9.2Revenue, Q4 FY2024, three months to 2024-12-31$9.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Report this figure1.5Revenue, Q1 FY2025, three months to 2025-03-31$1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure1.8Revenue, Q2 FY2025, three months to 2025-06-30$1.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure3.3Revenue, Q3 FY2025, three months to 2025-09-30$3.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure1.3Revenue, Q4 FY2025, three months to 2025-12-31$1.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Report this figure2.0Revenue, Q1 FY2026, three months to 2026-03-31$2.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure1.6Revenue, Q2 FY2026, three months to 2026-06-30$1.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(240.9%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$10.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Revenue: $4.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure(1082.1%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$99.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Revenue: $9.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Report this figure(1242.9%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$18.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Revenue: $1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure(1035.9%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$18.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Revenue: $1.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure(519.8%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$17.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Revenue: $3.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure(1755.5%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$22.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Revenue: $1.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Report this figure(1111.8%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$22.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Revenue: $2.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure(1487.9%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$24.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Revenue: $1.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure
Net margin%(174.6%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$7.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Revenue: $4.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure(1048.2%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$96.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Revenue: $9.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Report this figure(1036.8%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$15.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Revenue: $1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure(868.3%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$15.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Revenue: $1.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure(443.0%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$14.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Revenue: $3.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figure(1528.6%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$19.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Revenue: $1.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Report this figure(993.2%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$19.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Revenue: $2.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure(1320.1%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$21.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Revenue: $1.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure
Diluted EPS$ per share(0.11)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figurenot reported (Diluted EPS not reported)(0.12)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure(0.13)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure(0.12)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001104659-25-107788.Report this figurenot reported (Diluted EPS not reported)(0.15)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure(0.15)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001104659-26-092065.Report this figure
Free cash flow$m22.0Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $22.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001104659-25-107788. Derived: 9-month figure less the 6-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001104659-25-107788. Derived: 9-month figure less the 6-month figure.Report this figure(8.9)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$8.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Report this figure(13.1)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$13.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Capital expenditure: $43.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure(10.0)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$10.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001104659-26-092065. Derived: 6-month figure less the 3-month figure.Capital expenditure: $21.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001104659-26-092065. Derived: 6-month figure less the 3-month figure.Report this figure(11.0)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$10.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001104659-25-107788. Derived: 9-month figure less the 6-month figure.Capital expenditure: $23.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001104659-25-107788. Derived: 9-month figure less the 6-month figure.Report this figure(13.2)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$13.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Capital expenditure: $24.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001104659-26-020540. Derived: 12-month figure less the 9-month figure.Report this figure(18.2)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$18.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Capital expenditure: $13.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001104659-26-057202.Report this figure(19.9)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$19.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001104659-26-092065. Derived: 6-month figure less the 3-month figure.Capital expenditure: $58.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001104659-26-092065. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$7.8mOperating margin −975.9%
Diluted EPS−$0.53, FY2025
Free cash flow−$47.2m, FY2025
Aclaris Therapeutics, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m6.8Revenue, FY2021, twelve months to 2021-12-31$6.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-27, accession 0001558370-24-001753.Report this figure29.8Revenue, FY2022, twelve months to 2022-12-31$29.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-27, accession 0001558370-24-001753.Report this figure31.2Revenue, FY2023, twelve months to 2023-12-31$31.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-27, accession 0001558370-25-001819.Report this figure18.7Revenue, FY2024, twelve months to 2024-12-31$18.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020540.Report this figure7.8Revenue, FY2025, twelve months to 2025-12-31$7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020540.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(1327.1%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$89.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-27, accession 0001558370-24-001753.Revenue: $6.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-27, accession 0001558370-24-001753.Report this figure(302.0%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$89.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-27, accession 0001558370-24-001753.Revenue: $29.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-27, accession 0001558370-24-001753.Report this figure(311.6%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$97.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-27, accession 0001558370-25-001819.Revenue: $31.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-27, accession 0001558370-25-001819.Report this figure(758.2%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$141.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020540.Revenue: $18.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020540.Report this figure(975.9%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$76.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020540.Revenue: $7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020540.Report this figure
Net margin%(1344.0%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$90.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-27, accession 0001558370-24-001753.Revenue: $6.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-27, accession 0001558370-24-001753.Report this figure(292.1%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$86.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-27, accession 0001558370-24-001753.Revenue: $29.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-27, accession 0001558370-24-001753.Report this figure(283.1%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$88.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-27, accession 0001558370-25-001819.Revenue: $31.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-27, accession 0001558370-25-001819.Report this figure(705.5%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$132.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020540.Revenue: $18.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020540.Report this figure(829.6%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$64.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020540.Revenue: $7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020540.Report this figure
Diluted EPS$ per share(1.60)Diluted EPS, FY2021, twelve months to 2021-12-31−$1.60 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-27, accession 0001558370-24-001753.Report this figure(1.33)Diluted EPS, FY2022, twelve months to 2022-12-31−$1.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-27, accession 0001558370-24-001753.Report this figure(1.27)Diluted EPS, FY2023, twelve months to 2023-12-31−$1.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-27, accession 0001558370-25-001819.Report this figure(1.71)Diluted EPS, FY2024, twelve months to 2024-12-31−$1.71 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001104659-26-020540.Report this figure(0.53)Diluted EPS, FY2025, twelve months to 2025-12-31−$0.53 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001104659-26-020540.Report this figure
Free cash flow$m(52.4)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$52.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-27, accession 0001558370-24-001753.Capital expenditure: $308.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-27, accession 0001558370-24-001753.Report this figure(68.2)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$67.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-27, accession 0001558370-24-001753.Capital expenditure: $605.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-27, accession 0001558370-24-001753.Report this figure(79.6)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$78.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-27, accession 0001558370-25-001819.Capital expenditure: $1.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-27, accession 0001558370-25-001819.Report this figure(20.2)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$20.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001104659-26-020540.Capital expenditure: $121.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001104659-26-020540.Report this figure(47.2)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$47.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001104659-26-020540.Capital expenditure: $111.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001104659-26-020540.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Aclaris Therapeutics, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
RA CAPITAL MANAGEMENT, L.P.2026-06-30$67.3m12,723,026Added+5,918,954
BML Capital Management, LLC2026-06-30$63.3m11,975,000Reduced−2,275,000
BlackRock, Inc.2026-06-30$53.1m10,037,008Added+2,629,943
Deep Track Capital, LP2026-06-30$49.4m9,345,000Unchanged
Vivo Capital, LLC2026-06-30$35.4m6,694,637Added+27,971
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$30.8m5,817,866Added+650,397
Frazier Life Sciences Management, L.P.2026-06-30$26.1m4,925,374Unchanged
Rock Springs Capital Management LP2026-06-30$22.9m4,330,532Reduced−142,118
ADAGE CAPITAL PARTNERS GP, L.L.C.2026-06-30$21.5m4,071,000Added+200,000
Decheng Capital LLC2026-06-30$21.4m4,041,736Unchanged

Recent filings

All 859 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Aclaris Therapeutics, Inc., recent filings
FiledFormWhat it isAccession number
2026-10-2717:25 ET8-K1.01 Entry into a material agreement; 9.01 Financial statements and exhibits0001104659-26-119231
2026-10-2706:06 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001104659-26-118952
2026-08-0617:15 ET8-K1.01 Entry into a material agreement; 9.01 Financial statements and exhibits0001104659-26-092128
2026-08-0616:31 ET10-QQuarterly reportPeriod 2026-06-300001104659-26-092065
2026-08-0607:15 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001104659-26-091629
2026-06-0416:01 ET8-K5.07 Shareholder vote results0001104659-26-070494
2026-05-0716:32 ET10-QQuarterly reportPeriod 2026-03-310001104659-26-057202
2026-05-0707:15 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001104659-26-056669
2026-04-2806:45 ET8-K7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001104659-26-049733
2026-04-2307:45 ETDEF 14AProxy statementPeriod 2026-06-040001104659-26-047262

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 26, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, locked when the 8-K was accepted. It is scored when the 10-Q or 10-K is ingested.See the target

About the filer

CIK
1557746
Tickers
ACRS
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Non-accelerated filer<br>Smaller reporting company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:27 ET. Listed shows no prices and gives no investment advice.